Approving Proposition 4 would authorize $10 billion in debt to spend on environmental and climate projects, with the biggest chunk, $1.9 billion, for drinking water improvements. The bond prioritizes ...

WASHINGTON, DC – The Center for Strategic and International Studies (CSIS), a bipartisan, nonprofit policy research organization dedicated to advancing practical ideas to address the world’s greatest ...

Analysts have raised concerns around Dr Reddy’s Laboratories’ growth outlook after the pharmaceutical company posted a weaker-than-expected March quarter (Q4FY26) result. They believe a sharp decline ...

Pharma major Dr. Reddy’s Laboratories reported consolidated net profit slumped to ₹221.3 crore for the March quarter compared to ₹1,586.7 crore a year earlier on the back of lower sales and multiple ...

Dr Reddy shares: Shares of pharma major Dr Reddy's Laboratories swung between gains and losses in morning deals on the BSE on Wednesday, 13 May, a day after reporting a 86% year-on-year (YoY) drop in ...

Dr. Reddy's Laboratories shares: The pharma major posted a sharp 86% YoY drop in Q4FY26 consolidated net profit to Rs 221 crore, compared with Rs 1,587 crore a year ago. Following the weak earnings ...

Dr Reddy's Q4 net profit dropped 86% YoY to Rs 221 crore from Rs 1,593 crore Revenue declined 11.5% YoY to Rs 7,546 crore, missing analyst expectations EBITDA fell 60.4% YoY to Rs 981 crore with ...

NDTV Profit's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer ...

Hyderabad: Lower lenalidomide sales (Revlimid) in the North America markets dragged Dr Reddy’s Labs’ consolidated net profit by 86% for the fourth quarter ended March 31, 2026, to nearly Rs 221 crore ...

Dr Reddy's Laboratories (DRL) posted a sharp decline in net profit for the January–March quarter (Q4FY26), reporting earnings of ₹220 crore compared with ₹1,587.3 crore in the same period last year.

Dr Reddy's Q4 profit slumps 86% due to cancer therapy impairment Revenue falls 11.5% amid US pricing pressure and competition Lenalidomide sales drop; semaglutide eyed for future growth Drugmaker Dr ...